The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Professional Services Scientific, Architectural And Engineering Technical Activities Scientific Research And Development 72.11 - Research and experimental development on biotechnology
209 jobs Number of planned job losses
Announcement Date
7 March 2023
Employment effect (start)
22 June 2023
Foreseen end date
31 December 2023
Description
The Novartis group has announced the closure of its cell and gene therapy production site in Les Ulis (Essonne), which employs 209 people. Novartis bought the site in 2019 from the French Fractionation and Biotechnology Laboratory (LFB). The Swiss group had received 800,000 euros in subsidies from the stimulus plan to modernise the site.
The management announced this project to cease its CAR-T cell therapy production activities to employee representatives on 16 February. The information and consultation procedure for the implementation of a job protection plan began on 22 February. In accordance with the legislation, Novartis is required to look for a buyer before closing the site. Without a buyer by 22 June, 149 people will be made redundant then, and the remaining 60 - by the end of 2023.
At the end of 2022, Novartis had around 2,900 employees in France, including 1,436 jobs corresponding to medical sales representatives and the head office in Rueil-Malmaison (Hauts-de-Seine), with the remainder divided between two production sites. In Huningue (Alsace), around 800 people manufacture monoclonal antibodies, while in Les Ulis, 200 employees manufacture Kymriah, a cell therapy known as 'CAR T-Cell'. Novartis has alrerady announced a restructuring in January 2023, with 400 job cuts in France (FR-Novartis-2023a). At the day of the anouncement the management explained the two production sites located in Huningue and Les Ulis will not be affected.
Eurofound (2023), Novartis CellForCure, Closure in France, factsheet number 108625, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/108625.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
